Ventures

Ansana offers a smart sterilization container for surgical instruments, designed to tackle key challenges in the healthcare sector. By integrating electronic sensors, it ensures sterility in operating rooms, reducing the risk of infections by 10% and lowering the environmental impact of sterilization processes by 85%. Ansana's enhances patient safety with real-time monitoring and traceability features, with complex instruments like endoscopes, while also cutting costs for healthcare facilities in terms of labor and materials.

ImplantGuard is addressing the challenge of bacterial infections post-implant surgery, which affect millions of patients worldwide. Their solution involves coating implants with antimicrobials using a versatile and cost-effective process called plasma nitriding. This innovative coating technology offers a safer and more efficient alternative to existing implant coatings, potentially reducing the risk of infections and the need for costly surgical procedures.

XtRNA Bio is developing a pioneering gene therapy to treat Charcot Marie Tooth (CMT) disease type 2D, leveraging tRNA supplementation therapies. Their patented treatment targets mutations in tRNA synthetases, offering a new therapeutic modality with vast potential for various diseases. They are raising €5M to develop a clinical candidate for CMT2D and expand their pipeline. CMT, a hereditary and heterogeneous disease, affects 1 in 2500 people worldwide, causing progressive muscle wasting, loss of sensation, and chronic pain, with no current cure.

Heat2Move offers a revolutionizing approach to chronic back pain treatment. Unlike traditional methods relying on medications or heat patches, Heat2Move combines blue light and infrared warmth to enhance blood flow and muscle repair. This innovative solution provides therapists and patients with a new tool for managing chronic pain effectively. With its potential to make a significant impact on treatment options, BlueTouch offers hope for those suffering from back pain worldwide.

Exolvo Biosciences, a collaboration between NLC Health Ventures and Verily (Google) Life Sciences, is revolutionizing oral drug delivery for large molecules like biologics. Our smart capsule technology, originating from the Google X moonshot program, eliminates painful injections and maximizes medication effectiveness. With ongoing pre-clinical testing and plans for an IND package in the U.S., we're poised to redefine drug delivery standards.

TherageniX introduces an approach to improve bone implants by augmenting autologous bone grafts with regenerative gene therapies. Traditional bone repair methods face challenges like rejection, infection, and limited regenerative capacity. TherageniX's solution aims to enhance the regenerative bone grafts, improving functional outcomes and reducing donor trauma. This method bypasses regulatory and manufacturing hurdles, offering a promising advancement in bone grafting procedures.

NLC's venture, Profionics, advances Cardiff University's sepsis research with a biomarker test combining AI, gene expression, and metabolic analysis for rapid, accurate diagnosis. This test, which works in under 30 minutes with a drop of blood, surpasses traditional methods by quickly identifying those needing antibiotics and reducing unnecessary use, thus combating antimicrobial resistance and saving lives. Particularly impactful in neonatal care, it ensures timely detection critical for newborn survival. Founded by NLC, Cardiff University, and CEO Darren Fergus, Profionics leverages extensive research and a blood sample BioBank, positioning itself as a leader in host response diagnostic testing.

Sansepsis is a new treatment for sepsis, a serious condition causing many hospital deaths. Developed by Sanquin, a top blood bank in Europe, it uses a special filtering technology called apheresis to remove harmful pathogens from the blood. This innovative approach aims to improve patient outcomes and reduce the high costs associated with treating sepsis, offering hope for better management of this deadly condition.